Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Operating Expenses (2016 - 2025)

KalVista Pharmaceuticals' Operating Expenses history spans 11 years, with the latest figure at $55.0 million for Q2 2025.

  • For Q2 2025, Operating Expenses rose 13.57% year-over-year to $55.0 million; the TTM value through Apr 2025 reached $145.1 million, up 3.28%, while the annual FY2025 figure was $188.0 million, 33.86% up from the prior year.
  • Operating Expenses for Q2 2025 was $55.0 million at KalVista Pharmaceuticals, up from $45.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $55.0 million in Q2 2025 and bottomed at $12.7 million in Q1 2021.
  • The 4-year median for Operating Expenses is $38.7 million (2024), against an average of $37.3 million.
  • The largest annual shift saw Operating Expenses decreased 11.5% in 2021 before it skyrocketed 54.01% in 2024.
  • A 4-year view of Operating Expenses shows it stood at $12.7 million in 2021, then soared by 135.02% to $29.7 million in 2023, then soared by 54.01% to $45.8 million in 2024, then grew by 20.12% to $55.0 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Operating Expenses are $55.0 million (Q2 2025), $45.8 million (Q4 2024), and $44.2 million (Q3 2024).